Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens
Authors:
- Kyra J. FuchsKFKyra J. Fuchs
- Indu KhatriIKIndu Khatri
- Michel G. D. KesterMKMichel G. D. Kester
- Eva A. S. KosterEKEva A. S. Koster
- Georgia KoutsoumpliGKGeorgia Koutsoumpli
- Cornelis A. M. van BergenCBCornelis A. M. van Bergen
- Peter A. van VeelenPVPeter A. van Veelen
- Peter A. C. ’T HoenPHPeter A. C. ’T Hoen
- Peter van BalenPBPeter van Balen
Open Access
- 2 May 2024
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 143 (18) , 1856-1872
Abstract
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, antitumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy nonhematopoietic tissues of patients, thereby inducing side effects known as graft-versus-host disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT. To systematically identify novel MiHAs by genome-wide association screening, T-cell clones were isolated from 39 transplanted patients and tested for reactivity against 191 Epstein-Barr virus transformed B cell lines of the 1000 Genomes Project. By discovering 81 new MiHAs, we more than doubled the antigen repertoire to 159 MiHAs and demonstrated that, despite many genetic differences between patients and donors, often the same MiHAs are targeted in multiple patients. Furthermore, we showed that one quarter of the antigens are cryptic, that is translated from unconventional open reading frames, for example long noncoding RNAs, showing that these antigen types are relevant targets in natural immune responses. Finally, using single cell RNA-seq data, we analyzed tissue expression of MiHA-encoding genes to explore their potential role in clinical outcome, and characterized 11 new hematopoietic-restricted MiHAs as potential targets for immunotherapy. In conclusion, we expanded the repertoire of HLA-I-restricted MiHAs and identified recurrent, cryptic and hematopoietic-restricted antigens, which are fundamental to predict, follow or manipulate immune responses to improve clinical outcome after alloSCT.Keywords
This publication has 90 references indexed in Scilit:
- Associations of minor histocompatibility antigens with outcomes following allogeneic hematopoietic cell transplantationAmerican Journal of Hematology, 2023
- Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cellsDiabetologia, 2023
- Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patientsAnnals of Hematology, 2023
- Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease TissuesTransplantation and Cellular Therapy, 2019
- Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell SurfaceProteomics, 2018
- Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humansDiabetologia, 2013
- Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2013
- Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2013
- Effects of Mismatching for Minor Histocompatibility Antigens on Clinical Outcomes in HLA-Matched, Unrelated Hematopoietic Stem Cell TransplantsTransplantation and Cellular Therapy, 2009
- Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host diseaseBest Practice & Research Clinical Haematology, 2008